To date, the classification of cancers has been based solely on the phenotypic and genotypic characteristics of tumor cells. A new paradigm, scientifically well established and recommended by WHO guidelines, relies on the introduction of the immune response as a new prognostic parameter to predict and refine the clinical outcomes of cancer patients. Maximize patient survival rates with an assessment of the tumor immune response.
IMMUNOSCORE® IC is intended for the detection of PD-L1 protein and the concomitant detection of CD8 + cells in Non-Small Cell Lung cancer (NSCLC) tissue.